SCHEMBL9643236

SCHEMBL9643236

Cc1ccoc(=O)c1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580718 0.75
SCHEMBL27696854 0.75
SCHEMBL27718563 0.75
SCHEMBL16382260 0.73 KDM4E (0.54)
SCHEMBL28190794 0.69 KDM4E (0.48)
SCHEMBL10622956 0.68
SCHEMBL980904 0.68
SCHEMBL5609721 0.67
SCHEMBL24534291 0.66 CYP1A2 (0.54)
SCHEMBL11985815 0.66 MAPK1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0393901-A1 Ink composition ADGER KOGYO CO., LTD. (JP) 1990-10-24 EP claimed
CN-117924230-A Heterocyclic compound and application thereof as thermal activation delayed fluorescence receptor unit 中国石油化工股份有限公司 2024-04-26 CN disclosed
CN-107846945-A The purposes of composition, said composition comprising taste modulating compound and the food comprising said composition 威·曼父子有限公司 2018-03-27 CN disclosed
US-9265767-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2016-02-23 US disclosed
US-20150274706-A1 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS FMR LLC 2015-10-01 US disclosed
US-8933074-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2015-01-13 US disclosed
US-20140011808-A1 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS FMR LLC 2014-01-09 US disclosed
US-8466148-B2 1,2-disubstituted heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2013-06-18 US disclosed
US-8071595-B2 1,2-disubstituted heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-07-14 US disclosed
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-07-14 US disclosed
US-20100167178-A1 Oxime sulfonates and the use thereof as latent acids YAMATO HITOSHI 2010-07-01 US disclosed
US-20100167178-A1 Oxime sulfonates and the use thereof as latent acids YAMATO HITOSHI 2010-07-01 US disclosed
WO-2009150074-A1 SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2009-12-17 WO disclosed
WO-2007147782-A2 OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS CIBA HOLDING INC. (CH) 2007-12-27 WO disclosed
US-5082495-A INK COMPOSITION ADGER KOGYO CO., LTD. (JP) 1992-01-21 US disclosed
EP-0393901-A1 Ink composition ADGER KOGYO CO., LTD. (JP) 1990-10-24 EP disclosed